This study explore the efficacy, toxic and side effects and survival impact of apatinib combined with capecitabine chemotherapy for the second-line treatment of advanced esophageal cancer. The clinical data of 76 patients with advanced esophageal cancer treated from January 2015 to April 2020 have been retrospectively analyzed. They are divided into experimental and control groups according to different treatment methods. The experimental group (n=29) underwent oral apatinib targeted therapy (250 mg/once/d) combined with oral capecitabine chemotherapy (1000 mg/m2 according to the body surface area on D1-14). Maintenance therapy with apatinib has been conducted after 4-6 cycles. The control group (n=47) received the second-line chemotherapy. After more than 2 cycles of chemotherapy, complete response is achieved in 0 cases, partial response in 19 cases, stable disease in 6 cases, and progressive disease in 3 cases. Overall response rate (ORR) is found to be 67.86% and the disease control rate is 89.28%. The median progression-free survival (mPFS) and the median overall survival (mOS) are 6.7 months and 8.9 months, respectively. Karnofsky Performance Status score of 2 points, liver metastasis, elevation of tumor marker squamous cell carcinoma and unsatisfactory efficacy are independent prognostic factors. In control group, ORR was 34.04%, and mPFS and mOS are 3.9 months and 7.4 months, respectively. No severe drug-related toxic and side effects have been observed, except for 1 patient who voluntarily discontinued treatment due to grade III hypertension. Apatinib combined with capecitabine chemotherapy shows good overall efficacy with satisfactory safety and tolerance for the second-line treatment of advanced esophageal cancer.

中文翻译：

---

阿帕替尼联合卡培他滨化疗二线治疗晚期食管癌的疗效及生存分析

本研究探讨阿帕替尼联合卡培他滨化疗二线治疗晚期食管癌的疗效、毒副作用及对生存的影响。回顾性分析2015年1月至2020年4月收治的76例晚期食管癌患者的临床资料。根据治疗方法的不同分为实验组和对照组。实验组(n=29)接受口服阿帕替尼靶向治疗(250 mg/次/d)联合口服卡培他滨化疗(1000 mg/m2根据D1-14体表面积)。阿帕替尼维持治疗在 4-6 个周期后进行。对照组（n=47）接受二线化疗。化疗2个周期以上，完全缓解0例，部分缓解19例，病情稳定6例，病情进展3例。总缓解率 (ORR) 为 67.86%，疾病控制率为 89.28%。中位无进展生存期 (mPFS) 和中位总生存期 (mOS) 分别为 6.7 个月和 8.9 个月。Karnofsky Performance Status评分2分、肝转移、肿瘤标志物鳞状细胞癌升高和疗效不理想是独立的预后因素。对照组ORR为34.04%，mPFS和mOS分别为3.9个月和7.4个月。除1例因III级高血压自愿中止治疗外，未观察到严重的药物相关毒副作用。